Real-life data on Selexipag for the treatment of pulmonary hypertension
Selexipag is an orally available selective IP prostacyclin-receptor agonist licensed since 2016 for the therapy of pulmonary arterial hypertension (PAH). We aimed to describe real-life data of patients with pulmonary hypertension (PH) treated with selexipag. We analyzed all patients initiated with s...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2019-02-01
|
| Series: | Pulmonary Circulation |
| Online Access: | https://doi.org/10.1177/2045894019832199 |